MB
AUTL

MPM BioImpact’s Autolus Therapeutics AUTL Stock Holding History

MPM BioImpact’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39,740
Closed -$355K – 14
2020
Q4 		$355K Hold
39,740
– – 0.06% 13
2020
Q3 		$463K Hold
39,740
– – 0.11% 12
2020
Q2 		$637K Hold
39,740
– – 0.17% 11
2020
Q1 		$238K Hold
39,740
– – 0.15% 10
2019
Q4 		$525K Buy
+39,740
New +$520K 0.19% 12

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MPM BioImpact's AUTL Position: Q1 2021 in Review

MPM BioImpact sold out of Autolus Therapeutics (AUTL) in Q1 2021, closing a stake of 39,740 shares — an estimated $355K sold.

MPM BioImpact first reported a position in AUTL in Q4 2019 and held it in 5 quarters. The position peaked at $637K in Q2 2020. 63 funds tracked by Wall St. Rank hold AUTL as of Q1 2021.

  • MPM BioImpact reported no remaining Autolus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • MPM BioImpact sold 39,740 Autolus Therapeutics shares in Q1 2021, an estimated $355K.
  • MPM BioImpact first reported a position in Autolus Therapeutics in Q4 2019 and held it in 5 quarters.
  • MPM BioImpact's Autolus Therapeutics position peaked at $637K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2021.

Based on MPM BioImpact's 13F filing for Q1 2021, filed 13 May 2021.